Skip to main content

Table 1 Baseline characteristics and demographics

From: Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial

Variable Placebo (n = 17) Linagliptin (n = 14) P
Age (years), mean ± SD 63 ± 6 61 ± 5 0.21
Sex female, n % 10 (59%) 3 (21%) 0.04
Race 0.49
 BL 12 (71%) 8 (57%)
 Wh 4 (24%) 3 (21%)
 Other 1 (6%) 3 (21%)
Medications
 Metformin 14 (82%) 12 (86%) 0.99
 Insulin 6 (35%) 5 (36%) 0.99
BP
 Systolic 133 ± 18 128 ± 10 0.30
 Diastolic 77 ± 7 81 ± 7 0.23
 BMI 30.6 ± 2.9 31.2 ± 4.4 0.67
 Percent fat 38 ± 10 30 ± 10 0.04
 Waist cm 105 ± 8 107 ± 17 0.22
 Basic metabolic rate 1476 ± 448 1868 ± 293 0.02
 Fasting glucose 130 ± 44 125 ± 26 0.70
 Serum creatinine 0.9 ± 0.3 1.1 ± 0.4 0.24
 eGFR 84 ± 19 83 ± 21 0.85
 Cholesterol 168 ± 53 166 ± 52 0.92
 HbA1c 7.4 ± 1.0 7.1 ± 0.7 0.50